ExOcular develops blood‑based multiplex diagnostic tests that measure eye‑specific biomarkers isolated from exosomes to enable early detection, prognosis, and treatment monitoring of severe eye diseases such as diabetic retinopathy and age‑related macular degeneration. Their platform generates a quantitative Disease Severity Score, giving physicians actionable insights for risk stratification and personalized therapy decisions. The exosome‑derived biomarkers provide higher concentration and stability, improving test reproducibility and clinical utility.
Funding
Funding not disclosed
Founders
Product
Problem
Diagnosing, prognosing, and monitoring severe eye diseases such as diabetic retinopathy and age‑related macular degeneration currently relies on invasive ocular imaging and subjective clinical assessments, which can be costly, require specialist equipment, and may miss early disease changes.
Solution
ExOcular offers blood‑based multiplex tests that isolate eye‑specific biomarkers from circulating exosomes. By quantifying these biomarkers, the platform generates a numeric Disease Severity Score that reflects disease stage and progression. The exosome‑derived markers are protected from degradation and concentrated, enabling reproducible measurement compared with direct plasma assays. Clinicians receive objective, early‑stage risk stratification and can track treatment response over time, supporting more timely referrals and personalized therapeutic decisions.
Target Audience
Primary customers are ophthalmologists, retina specialists, and endocrinology clinics managing patients at risk for diabetic retinopathy or age‑related macular degeneration, as well as pharmaceutical companies conducting ocular drug trials.
Features
- Multiplex assay panel targeting a validated set of eye‑specific exosomal proteins, DNA, and RNA biomarkers
- Proprietary algorithm that converts biomarker levels into a quantitative Disease Severity Score
- Blood draw workflow compatible with standard clinical laboratory processes
- High analytical reproducibility due to exosome lipid‑bilayer protection of cargo
- Ability to use the same panel for diagnosis, prognosis, and longitudinal treatment monitoring